Astellas Pharma

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. World-renowned experts from NCCN Member Institutions diagnose and treat patients with a broad spectrum of cancers and are recognized for dealing with complex, aggressive, or rare cancers. NCCN Member Institutions pioneered the concept of the multidisciplinary team approach to patient care and conduct innovative research that contributes significantly to understanding, diagnosing, and treating cancer. NCCN programs offer access to expert physicians, superior treatment, and quality and safety initiatives that continuously improve the effectiveness and efficiency of cancer care.

Iota Biosciences, Inc. is a medical device company based in Berkeley, California, founded in 2017. The company specializes in developing wireless sensors and devices that monitor, measure, and stimulate internal nerves, muscles, and organs for electroceutical applications, particularly in the treatment of immune and neural disorders. Iota Biosciences has pioneered a neural dust technology that employs implantable, mote-sized ultrasonic sensors, allowing for completely wireless and untethered neural recordings in the brain. This innovation eliminates the need for invasive wiring through the skull, enabling real-time wireless cortical recording and improving the monitoring and treatment of various diseases. As of late 2020, Iota Biosciences operates as a subsidiary of Astellas Pharma Inc.

Nanna Therapeutics is a drug discovery company addressing age-related diseases for which others are failing to provide effective treatments. These include mitochondrial, neurodegenerative, cardiovascular or metabolic, joint or tissue disease as well as cancer. Nanna Therapeutics are targeting fundamental cellular processes to create drugs to treat age-related diseases and improve longevity. Such drugs include those to combat debilitating neurodegenerative, inflammatory, cardiovascular and metabolic diseases as well as many cancers. With a strong focus on mitochondria, the energy source in every cell, we can target the fundamental causes of many age-related diseases. Through this approach we can also address debilitating, life-limiting mitochondrial diseases for which there are currently few effective therapies. Nanna Therapeutics has developed a tightly integrated set of proprietary technologies that radically disrupt current methods of creating new medicines. This Totally Integrated Medicines Engine (TIME) has been devised to answer the needs of drug discovery and development scientists utilising the best in 21st century technologies of microfluidics, nanofabrication and artificial intelligence.

Xyphos Biosciences develops a CAR-T cell therapy platform called ACCEL (Advanced Cellular Control through Engineered Ligands), for treating relapsed hematological malignancies and solid tumors. The platform enables precise control of activity and targeting of universal CAR-T cell, termed convertibleCAR-T, using any tumor-specific full antibody and can add critical functionality to convertibleCAR-T cells.

Audentes Therapeutics is a clinical-stage biotechnology company dedicated to developing and commercializing gene therapy products for patients with serious, life-threatening rare diseases caused by single gene defects. The company is advancing several therapies, including AT132, currently in Phase I/II clinical trials for X-linked myotubular myopathy, and AT342, also in Phase I/II studies for Crigler-Najjar syndrome. Additionally, Audentes is exploring AT845 in preclinical studies for Pompe disease and AT307 for the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. The company is also working on vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. Collaborations include a partnership with Genethon for XLMTM treatments and an agreement with the University of Pennsylvania for Crigler-Najjar syndrome products. Founded in 2012 and headquartered in San Francisco, California, Audentes Therapeutics operates as a subsidiary of Astellas US Holding, Inc.

LabCentral is a provider of business incubation and acceleration services aimed at supporting startup entrepreneurs in the life sciences sector. It offers essential resources such as mentorship, coaching, and collaborative workspaces to facilitate the growth of emerging companies. Additionally, LabCentral organizes promotional events that connect entrepreneurs with potential investors, fostering opportunities for funding and business development. The facility has attracted companies like Conkwest, Inc., which focuses on developing novel cell-based treatments for cancer and viral infections. Through its comprehensive support system, LabCentral plays a vital role in nurturing innovation and advancing research in the biotech field.

Iota Biosciences, Inc. is a medical device company based in Berkeley, California, founded in 2017. The company specializes in developing wireless sensors and devices that monitor, measure, and stimulate internal nerves, muscles, and organs for electroceutical applications, particularly in the treatment of immune and neural disorders. Iota Biosciences has pioneered a neural dust technology that employs implantable, mote-sized ultrasonic sensors, allowing for completely wireless and untethered neural recordings in the brain. This innovation eliminates the need for invasive wiring through the skull, enabling real-time wireless cortical recording and improving the monitoring and treatment of various diseases. As of late 2020, Iota Biosciences operates as a subsidiary of Astellas Pharma Inc.

Potenza Therapeutics, Inc. is a preclinical-stage biotechnology company based in Cambridge, Massachusetts, founded in 2014. The company focuses on developing a portfolio of oncology programs that harness the body's immune system to identify and eliminate tumors. Potenza's innovative approach is rooted in understanding the biological mechanisms by which cancer cells evade immune detection and destruction. By leveraging these insights, the company aims to create effective pharmaceuticals that enhance the health outcomes of cancer patients.

Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. Our initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.

Heartseed Inc., founded in 2015 and based in Tokyo, Japan, focuses on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company aims to advance the clinical application of regenerative medicine specifically for treating heart disease. Heartseed is dedicated to creating cardiomyocyte replacement therapies derived from iPS cells to address advanced heart failure, aspiring to transform the treatment landscape for patients suffering from this condition.

Universal Cells Inc. is a biotechnology company based in Seattle, Washington, focused on developing, licensing, and commercializing stem cell therapies. Founded in 2013, the company specializes in engineering stem cells to prevent the expression of polymorphic human leukocyte antigen (HLA) molecules, which eliminates the risk of donor tissue rejection. This innovation allows for the creation of Universal Donor Stem Cells that are compatible with all patients, thus facilitating the development of off-the-shelf therapeutic products. Universal Cells employs proprietary gene editing technology, specifically recombinant adeno-associated virus (rAAV) mediated gene editing, to modify chromosomal genes without using genotoxic nucleases. As of 2018, Universal Cells operates as a subsidiary of Astellas Pharma Inc., furthering its mission to accelerate the development of cell therapies for various diseases and conditions.

Mitobridge, Inc., a biotechnology company, discovers and develops novel small molecule therapeutics that improve mitochondrial functions. Its product under pipeline includes MA-0211 (MTB-1), a clinical compound that is orally bioavailable PPARd modulator that aims to reverse the mitochondrial deficits in Duchenne muscular dystrophy patients. Mitobridge, Inc. was formerly known as Mitokyne, Inc. and changed its name to Mitobridge, Inc. in February 2015. The company was incorporated in 2011 and is based in Cambridge, Massachusetts. As of January 23, 2018, Mitobridge, Inc. operates as a subsidiary of Astellas Pharma Inc.

Catalia Health Inc. is a San Francisco-based company that develops a cloud-based patient care management platform aimed at enhancing healthcare delivery. Established in 2014, the company integrates artificial intelligence, psychology, and medicine to improve patient engagement and support. Its platform provides healthcare providers with real-time data on patient progress and challenges, facilitating effective communication through mobile apps, web interfaces, and an interactive robotic coach. By delivering tailored conversations to patients, Catalia Health aims to address ongoing healthcare issues, ultimately enabling healthcare professionals to monitor adherence to treatment and improve overall patient outcomes.

Ogeda SA, a clinical-stage drug discovery company, invents and develops small molecule drugs targeting G-Protein Coupled Receptors. It offers fezolinetant (ESN364), a Phase II clinical development product for the treatment of women’s health disorders; NK3 antagonists for the treatment of hormone-dependent pathologies in women's health; and products for endocrine, CNS/inflammatory disorders. Ogeda SA was formerly known as Euroscreen SA and changed its name to Ogeda SA in October 2016. The company was founded in 1994 and is based in Gosselies, Belgium. It has a meeting facility in Brussels, Belgium; and an additional office in Paris, France. Ogeda SA operates as a subsidiary of Astellas Pharma Inc.

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company that specializes in developing and commercializing regenerative therapies for ophthalmic conditions. The company is focused on creating innovative treatments for diseases such as Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration, with its most advanced products currently undergoing clinical trials. Ocata possesses a robust intellectual property portfolio that includes pluripotent stem cell platforms, specifically human embryonic stem cells and induced pluripotent stem cells, alongside other research initiatives in cell therapy.

Mitobridge, Inc., a biotechnology company, discovers and develops novel small molecule therapeutics that improve mitochondrial functions. Its product under pipeline includes MA-0211 (MTB-1), a clinical compound that is orally bioavailable PPARd modulator that aims to reverse the mitochondrial deficits in Duchenne muscular dystrophy patients. Mitobridge, Inc. was formerly known as Mitokyne, Inc. and changed its name to Mitobridge, Inc. in February 2015. The company was incorporated in 2011 and is based in Cambridge, Massachusetts. As of January 23, 2018, Mitobridge, Inc. operates as a subsidiary of Astellas Pharma Inc.

Telsar Pharma Inc., a new company that will develop an Astellas drug for a common inflammatory bowel disease.

OSI Pharmaceuticals strives to improve the health and quality of life for patients, develop breakthrough treatment options for physicians, offer rewarding careers to employees, and deliver value to our shareholders. The strategy is to build on the success of our flagship product, Tarceva® (erlotinib), and continue to invest in clinical and pre-clinical drug candidates in oncology, diabetes and obesity to provide longer-term growth. OSI has evolved to become a scientifically strong and financially successful top-tier biopharmaceutical company that is focused on disease areas that impact virtually every family in the world. The Oncology team is dedicated to the discovery and development of molecular targeted therapies to revolutionize the way cancer is treated and improve treatment outcomes. The Diabetes & Obesity team is dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. The strategy for this business team is to advance a pipeline of innovative diabetes and obesity research projects through clinical proof-of-concept studies, with a view to then potentially seeking financially attractive development and commercialization partnerships for these research programs. The goal is to pave the way for the future of oncology, diabetes and obesity treatments. They believe that our Company strategy is poised to deliver a rich pipeline of promising drug candidates that have the potential to significantly improve the treatment options available to patients today.

Agensys is a biotechnology company focused on the research and development of therapeutic human monoclonal antibodies and antibody-drug conjugates specifically for cancer treatment. The company offers products aimed at addressing various tumors, including those associated with prostate, pancreatic, bladder, kidney, lung, and colon cancers. Founded in 1997 and based in Santa Monica, California, Agensys operates as a subsidiary of Astellas Pharma US, Inc. It is dedicated to providing innovative therapeutic solutions to improve patient outcomes in oncology.